EDWARDS LIFESCIENCES EDWARDS INTUITY ELITE VALVE SYSTEM; HEART-VALVE, NON-ALLOGRAFT TISSUE
|
Back to Search Results |
|
Model Number 8300AB |
Device Problems
Fluid/Blood Leak (1250); Perivalvular Leak (1457); Detachment of Device or Device Component (2907)
|
Patient Problem
Insufficient Information (4580)
|
Event Date 06/27/2022 |
Event Type
Injury
|
Manufacturer Narrative
|
Valve dehiscence may occur early or late.When it occurs in the early post-operative period, it is typically a result of an inadequate prosthetic valve implantation in combination with friable myocardial tissue.Late dehiscence can occur as a result of successive dilatation of cardiac structures that result from progression of disease.The device was not returned for evaluation, as device request is ongoing.The investigation is still in progress; therefore, a conclusion has yet to be established.A supplemental report will be submitted accordingly upon investigation completion.
|
|
Event Description
|
Through implant patient registry, it was learned that a 23mm aortic valve was explanted after an implant duration of 3 years, 1 month due to severe perivalvular leak with severe eccentric regurgitation secondary to dehiscence.The explanted valve was replaced with a 23mm aortic valve.Per medical records a small pvl was noted on echo a year ago, recent echo showed pvl progressed to severe level.A tee demonstrated evidence of partial dehiscence of the valve with severe eccentric regurgitation from 2 perivalvular jets.The or tee confirmed severe aortic perivalvular regurgitation.Intra-operatively there was dehiscence of the subvalvular cuff from the annulus in the area of the right coronary sinus, leaving a large gap.There was no evidence to suggest infection.A post implant tee demonstrated the 23mm 11500a aortic valve was seated nicely and there was no pvl.The patient was transported to thoracic icu in stable condition and was discharged on pod #1.Pathology of the explanted aortic valve showed no calcification, no cusp tears, no thrombus and no obstructive fibrous ingrowth.Edwards lifesciences maintains an implant patient registry.This registry is a patient tracking mechanism for serialized edwards implantable devices (bioprosthetic heart valves and annuloplasty rings), rather than a true post-market surveillance registry.Through the registry, edwards is notified when these devices are implanted.In addition, patient and/or device status may be reported to the registry via the implantation data cards.The information is received from various sources (e.G.Surgeon, hospital and patient family members) and is not received in the form of a conventional "customer complaint." the information reported may or may not be related to the edwards device.
|
|
Manufacturer Narrative
|
H10: additional narratives.Updated d4, h4, and h6 per new information received.A definitive root cause cannot be conclusively determined; however, patient and/or procedural factors likely caused or contributed.The device history record (dhr) was reviewed and showed that this device met all manufacturing and sterilization specifications for product release prior to distribution.No issues were identified that would have impacted this event.Edwards will continue to review and monitor all events.Trends are monitored on a monthly basis and if action is required, appropriate investigation will be performed.
|
|
Search Alerts/Recalls
|
|
|